RVTYRevvity Inc.

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Prahlad R. Singh

Location

Massachusetts, USA

Exchange

NYSE

Website

https://perkinelmer.com

Summary

Revvity, Inc.

Company Info

CEO

Prahlad R. Singh

Location

Massachusetts, USA

Exchange

NYSE

Website

https://perkinelmer.com

Summary

Revvity, Inc.

AI Insights for RVTY
5 min read

Quick Summary

Revvity, Inc. is a diagnostics and life sciences company serving healthcare, research, pharmaceutical, biotechnology, and applied laboratory markets worldwide. The company operates mainly through Discovery & Analytical Solutions and Diagnostics, selling instruments, reagents, software, assays, workflow tools, and services that support disease detection, drug discovery, newborn screening, reproductive health, and laboratory automation. Revvity was formerly known as PerkinElmer and became a more focused life sciences and diagnostics company after divesting its Applied, Food and Enterprise Services business. Its main customers include clinical laboratories, hospitals, public health programs, biopharma companies, academic research institutions, diagnostic testing providers, and industrial or applied testing organizations. The company is headquartered in Massachusetts and is led by CEO Prahlad R. Singh, with a global workforce of about 16,700 employees.

Strengths

•

Revvity’s primary strength is its focused portfolio in diagnostics, life sciences tools, and specialized laboratory workflows after the separation from the legacy PerkinElmer applied services business.

•

The company has recurring revenue potential from reagents, consumables, service contracts, software, and installed diagnostic platforms.

•

It has recognized capabilities in newborn screening, reproductive health, immunodiagnostics, and research tools, which are markets with meaningful clinical and scientific importance.

•

The Signals software business and AI-enabled workflow launches show that Revvity is investing in higher-margin, data-driven products.

•

The company also has a global presence, a sizable employee base, strong gross profit generation, and shareholder-return flexibility through a large buyback authorization.

Key Risks

•

Revvity faces external risks from China procurement weakness, healthcare budget constraints, foreign exchange headwinds, and slower pharma or biotech research spending.

•

Competitive pressure from larger companies such as Thermo Fisher, Danaher, Roche, Siemens Healthineers, Abbott, Agilent, and Bio-Rad may limit pricing power or market share gains.

•

Regulatory, quality, cybersecurity, and data privacy requirements are important because Revvity operates in diagnostics, software, and clinical laboratory workflows.

•

Execution risk is also meaningful because the company is still proving that the post-PerkinElmer transformation can deliver higher growth, higher margins, and more recurring revenue.

What to Watch

During the most recent reported news quarter, Revvity delivered Q3 revenue that was roughly in line with expectations and adjusted EPS that exceeded analyst estimates.
The company reaffirmed full-year revenue guidance of about $2.86 billion and raised adjusted EPS guidance to $4.95.
Despite the earnings beat, investors focused on weak organic growth, margin pressure, and ongoing softness in China diagnostics.
Operating margin declined from the prior year, which raised questions about the pace of profitability improvement.
The quarter also included strategic emphasis on software, reproductive health, newborn screening, AI-enabled workflow tools, cost controls, and a new $1 billion share repurchase authorization.

Price Drivers

•

RVTY’s stock price is driven by reported revenue growth, organic growth trends, adjusted EPS performance, operating margin movement, and management guidance.

•

Recent Q3 2025 news showed revenue of $698.9 million, up 2.2% year over year, with adjusted EPS of $1.18 beating estimates, but the stock reacted negatively because organic growth was only 1% and margins declined.

•

Investors are focused on whether the company can restore stronger organic growth after its transformation from PerkinElmer into a more focused diagnostics and life sciences company.

•

China diagnostics weakness, pharma and biotech spending trends, foreign exchange headwinds, and procurement pressures can all materially affect sentiment.

•

Valuation also matters because the provided fundamentals show a high price-to-earnings ratio, elevated EV-to-EBITDA, and low earnings yield, meaning the market expects durable growth and margin improvement.

Recent News

•

Recent news highlighted Revvity’s Q3 2025 results, with revenue of $698.9 million, adjusted EPS of $1.18, and adjusted EBITDA of $284.5 million.

•

The company reaffirmed full-year revenue guidance and raised adjusted EPS guidance, but the market reacted negatively because organic growth was only 1% and operating margin declined.

•

Revvity also launched Revvity Transcribe AI, an OCR tool designed to digitize handwritten test request forms and improve newborn screening workflows.

•

Another notable development was the company’s transformation from PerkinElmer into Revvity after selling the Applied, Food and Enterprise Services business to New Mountain Capital.

•

News also tied Revvity to growth markets such as autoimmune diagnostics, Alzheimer’s-related genotyping, newborn screening, and AI-enabled laboratory automation.

Market Trends

•

Broader market trends affecting Revvity include growth in diagnostics, laboratory automation, precision medicine, newborn screening, reproductive health, and autoimmune disease testing.

•

The autoimmune diagnostics market is expected to grow at a healthy rate, supported by rising disease prevalence, earlier diagnosis, multiplex assays, biomarker tests, and automated platforms.

•

Laboratories are increasingly adopting software, AI, OCR, data integration, and workflow automation to improve speed, reduce errors, and handle higher testing volumes.

•

At the same time, life sciences tools companies are dealing with uneven pharma and biotech spending, China healthcare procurement pressure, and customer caution around capital equipment purchases.

•

Revvity’s performance will depend on whether it can align with the positive long-term trends while managing near-term macro, regional, pricing, and margin pressures.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on RVTY

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@democratiCrayn 10 months ago

Market recap: JPM misses earnings, CPI steady at 2.7%, and Fed Chair under investigation

Market recap: JPM misses earnings, CPI steady at 2.7%, and Fed Chair under investigation

post thumbnail

No more topics to show